Albert D M
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison Medical School, 53792-3220, USA,
Am J Ophthalmol. 1997 Jun;123(6):729-41. doi: 10.1016/s0002-9394(14)71119-5.
To trace the evolution and status of our knowledge of choroidal melanoma with regard to the nature, cause, and treatment of this tumor.
Historical materials beginning with Georg Bartisch's contributions in 1583 through to the Collaborative Ocular Melanoma Study and recent basic research are reviewed.
Many individuals have made important contributions to our knowledge about this tumor. Basic information, however, regarding the natural history of the tumor, the most effective treatment, and its cause is lacking.
The Collaborative Ocular Melanoma Study will provide important information regarding the choice of treatment between enucleation and radiotherapy as well as natural history information, quality of life, and definitive pathology findings. Definitive treatment of choroidal melanoma will depend on knowledge of the genetic defects that cause the tumor. Within the next 25 years, it is predicted that genetic defects will be determined and tumor samples will be obtained using small-needle aspiration and DNA probes located on microchips. In addition, treatment will then be based on drugs designed to inhibit molecules related to the genetic defect in the tumor.
探讨脉络膜黑色素瘤在肿瘤性质、病因及治疗方面的知识演变及现状。
回顾自1583年乔治·巴蒂施的贡献开始至协作性眼黑色素瘤研究及近期基础研究的历史资料。
许多人对我们关于这种肿瘤的认识做出了重要贡献。然而，关于肿瘤自然史、最有效治疗方法及其病因的基本信息仍很缺乏。
协作性眼黑色素瘤研究将提供关于眼球摘除术和放射治疗之间治疗选择的重要信息，以及自然史信息、生活质量和确切的病理检查结果。脉络膜黑色素瘤的确切治疗将取决于对导致肿瘤的基因缺陷的了解。预计在未来25年内，将确定基因缺陷，并使用小针穿刺和微芯片上的DNA探针获取肿瘤样本。此外，那时的治疗将基于旨在抑制与肿瘤基因缺陷相关分子的药物。
